Neuronetics Inc. (NASDAQ: STIM) stock gained by 2.91% at last close while the STIM stock price surges by 5.65% in the after-hours trading session. Neuronetics, Inc. is an advertising medical technology business that focuses on creating, manufacturing, and selling solutions that help people with mental illnesses live better lives.
STIM stock’ Recent Development
Neuronetics has launched a new website to address customer demand for information on innovative depression therapies. Healthcare practitioners will be able to learn more about this essential therapy option for their patients’ thanks to the improved site. The leading non-drug and non-invasive transcranial magnetic stimulation (TMS) solution for depression is NeuroStar Advanced Therapy for Mental Health.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
According to the latest market research study commissioned by Neuronetics, 67 percent of patients with Major Depressive Disorder (MDD) are not satisfied with their current treatment, 60 percent wish there were better options, and 56 percent are very interested in learning about new depression treatment options, highlighting the critical need for more mental health resources and awareness on a national level. In response to the findings, the Company has redesigned its website to provide new material in a consolidated center that reflects what patients need to make educated decisions regarding depression treatment.
Keith J. Sullivan, President, and CEO of Neuronetics commented,
They are a firm dedicated to helping people get better and changing their lives. It is more critical than ever to empower patients and clinicians with the skills they need to combat depression as they confront a mental health crisis on the wake of the COVID-19 epidemic. Especially because they know that many patients are dissatisfied with their existing therapies and are interested in novel treatments like NeuroStar. One of the many ways they are making it simpler for people to deal with depression is by improving the user experience and updating their website to emphasize trustworthy, need-to-know information about NeuroStar as a therapy option.